drugset / Trial / NCT04309721

Perampanel in Focal Status Epilepticus

NCT04309721

Phase 3 Terminated 1 enrolled Assistance Publique - Hôpitaux de Paris
RandomizedParallel-groupDouble-blindTreatment

Summary

Randomized controlled trial on focal motor status epilepticus (SE), studying the add-on efficacy of the enteral administration of perampanel (PER) to a conventional intravenous antiepileptic drug.

Timeline

Start
2022-11-02
Primary completion
2022-11-02
Completion
2023-11-13

Drugs

EvaluationDrugModalityDoseRoute
Subject Perampanel Small molecule 12 mg Oral